Advances in Hemophilia A: Expert Guidance and Practical Case Discussions

Join us for this live, CME-certified symposium featuring review and discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the treatment of hemophilia.

You will have multiple opportunities to interact with faculty through interactive patient case scenarios and dynamic question and answer sessions.

Sign up now! Registration is complimentary.

Friday Satellite Symposium preceding the 61st ASH Annual Meeting & Exposition.

Agenda

12:30 PM – 1:00 PM Lunch and Registration

1:00 PM – 1:15 PM Welcome and Introduction

1:15 PM – 1:45 PM New Developments in Nonfactor Replacement Strategies for Hemophilia A

1:45 PM – 2:15 PM Implementing an Individualized Care Approach in Hemophilia A

2:15 PM – 2:45 PM Panel Discussion: Clinical Challenges in Applying New Evidence to Practice in Hemophilia A Care

2:45 PM – 3:15 PM New Developments in Factor Replacement for Hemophilia A

3:15 PM – 3:45 PM Future Directions

3:45 PM – 4:00 PM Final Thoughts and Audience Question and Answer Session

Faculty

Program Director
Guy A. Young, MD

Professor of Pediatrics
Director
, Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Faculty
Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Children's Hospital of Michigan
Detroit, Michigan

Faculty
Stacy E. Croteau, MD, MMS

Director, Hemophilia/VWD Program
Boston Childrens Hospital
Associate Director, Boston Hemophilia Center
Assistant Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

Faculty
Cindy Leissinger, MD

Director
Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in integrating optimal therapy into the treatment of patients with hemophilia.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with hemophilia A.

Learning Objectives

  • Implement individualized hemophilia A management strategies that optimize adherence, outcomes, and utilization of resources
  • Analyze recent data on the efficacy, safety, and tolerability of emerging nonfactor replacement strategies for the management of hemophilia A with and without inhibitors
  • Discuss progress in the management of hemophilia A with factor-based interventions, including use of prolonged half-life agents
  • Develop approaches for individualizing therapy based on patient- and disease-specific characteristics
  • Evaluate available data for novel agents and treatment strategies and determine patients with Hemophilia A who may be eligible for a clinical trial

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.